| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 10,000 | $39.86 | $398,558.00 | -26.7% | |
| Jun 1, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 15,000 | $17.01 | $255,201.00 | -31.6% | |
| Jun 1, 2017 | PAHC Phibro Animal Health Corp | Dagger Thomas G | SVP, Gen Counsel &Corp Secy | Sell | 12,200 | $35.76 | $436,272.00 | -100% | |
| Jun 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $57.49 | $86,235.00 | -15.8% | |
| Jun 1, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 46,261 | $23.93 | $1,107,072.52 | -1.0% | |
| May 31, 2017 | CPIX Cumberland Pharmaceuticals Inc | Griggs Jonathan | Director | Sell | 8,000 | $6.97 | $55,760.00 | -42.5% | |
| May 31, 2017 | SNY Sanofi | Sanofi | 10% Owner | Buy | 297,501 | $71.87 | $21,381,396.87 | +2.9% | |
| May 31, 2017 | CPIX Cumberland Pharmaceuticals Inc | Bonner Michael | Chief Financial Officer | Buy | 300 | $6.95 | $2,085.00 | +2.0% | |
| May 31, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 11,482 | $16.92 | $194,300.39 | -2.3% | |
| May 30, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 4,297 | $16.93 | $72,730.59 | -4.7% | |
| May 26, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 2,500 | $35.90 | $89,757.50 | -6.3% | |
| May 26, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 5,353 | $25.14 | $134,592.44 | -0.1% | |
| May 25, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 5,500 | $34.90 | $191,950.00 | -6.2% | |
| May 25, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 48,000 | $34.67 | $1,664,160.00 | -20.0% | |
| May 25, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 48,000 | $34.67 | $1,664,160.00 | -20.0% | |
| May 24, 2017 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 25,000 | $57.42 | $1,435,535.00 | -3.8% | |
| May 24, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 17,451 | $25.01 | $436,364.00 | -0.7% | |
| May 23, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 10,000 | $53.39 | $533,900.00 | -8.5% | |
| May 22, 2017 | ANIK Anika Therapeutics, Inc. | Thompson Jeffery S | Director | Sell | 10,725 | $47.39 | $508,273.62 | -32.7% | |
| May 22, 2017 | AVDL Avadel Pharmaceuticals Plc | Stapleton Craig R | Director | Buy | 31,013 | $9.85 | $305,326.74 | +15.3% | |
| May 19, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Pernock David | Pres. &Chief Comm. Officer | Buy | 255 | $79.69 | $20,320.95 | +35.9% | |
| May 19, 2017 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 2,500 | $10.00 | $25,000.00 | +1.1% | |
| May 19, 2017 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 9,960 | $53.63 | $534,154.80 | -27.7% | |
| May 19, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 48,000 | $34.15 | $1,639,200.00 | -29.1% | |
| May 19, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 48,000 | $34.15 | $1,639,200.00 | -29.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.